The Lung Transplant Program at the Cooley Transplant Center at Baylor St. Luke's Medical Center has been performing successful lung and heart-lung transplants since the 1990s.
Lung transplants may be recommended for patients with severe end-stage lung disease caused by emphysema, cystic fibrosis, chronic diseases such as sarcoidosis, idiopathic pulmonary fibrosis (permanent scarring and thickening of lung tissue), pulmonary hypertension or congenital diseases. After a thorough evaluation, recommendations may include either single lung transplant, double lung transplant or heart and lung transplant.
The Breathing Lung Transplant Program describes a mode of transplantation where the donor lung is kept breathing and warm, with blood pumping through it from the time of the donor procedure all the way to the recipient implant. This utilizes a technology known as ex-vivo lung perfusion (EVLP), which has several components that allow the lung to remain in a physiologic state throughout transportation.
The organ care system (OCS) is the only portable EVLP system in the world and the only EVLP system that has undergone a positive FDA panel review in the United States as well as two rigorous international clinical trials. Interim trial results suggest that donor lungs in ideal condition transported in the OCS according to protocol had a 50-percent reduction in the incidence of graft dysfunction compared to those transported in standard ice coolers.
Because an estimated 5-10 percent of donor lung offers meet “standard or ideal conditions,” the EXPAND I trial was conducted to see the effect of the OCS on lungs that were outside of the ideal scenario. The EXPAND I interim results suggested 88 percent utilization of such lungs. That means double the number of potentially transplantable organs and a reduction in the time patients spend on the waitlist. For questions regarding the OCS, please call 832-355-3000.
Baylor St. Luke’s Medical Center is the first site in the nation to begin the EXPAND II clinical trial and the first site in Texas to utilize the OCS lung platform. In the EXPAND II trial, we will compare transplantation using the OCS in extended criteria donors to the outcomes of standard ice transplantation in standard donors. For more information on this trial, please contact us at 713-798-2267.